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PPARδ regulates satellite cell proliferation and
skeletal muscle regeneration
Alison R Angione1, Chunhui Jiang1, Dongning Pan2, Yong-Xu Wang2 and Shihuan Kuang1,3*
Abstract
Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear receptors that play important roles in
development and energy metabolism. Whereas PPARδ has been shown to regulate mitochondrial biosynthesis and
slow-muscle fiber types, its function in skeletal muscle progenitors (satellite cells) is unknown. Since constitutive
mutation of Pparδ leads to embryonic lethality, we sought to address this question by conditional knockout (cKO)
of Pparδ using Myf5-Cre/Pparδflox/flox alleles to ablate PPARδ in myogenic progenitor cells. Although Pparδ-cKO mice
were born normally and initially displayed no difference in body weight, muscle size or muscle composition, they
later developed metabolic syndrome, which manifested as increased body weight and reduced response to
glucose challenge at age nine months. Pparδ-cKO mice had 40% fewer satellite cells than their wild-type
littermates, and these satellite cells exhibited reduced growth kinetics and proliferation in vitro. Furthermore,
regeneration of Pparδ-cKO muscles was impaired after cardiotoxin-induced injury. Gene expression analysis showed
reduced expression of the Forkhead box class O transcription factor 1 (FoxO1) gene in Pparδ-cKO muscles under
both quiescent and regenerating conditions, suggesting that PPARδ acts through FoxO1 in regulating muscle
progenitor cells. These results support a function of PPARδ in regulating skeletal muscle metabolism and insulin
sensitivity, and they establish a novel role of PPARδ in muscle progenitor cells and postnatal muscle regeneration.
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Background
Skeletal muscle is the most abundant tissue in mam-
mals, making up 45% to 55% of total body mass in
humans, and plays important roles in body movement
and metabolic regulation. Muscle is made up of different
fiber types which have different metabolic requirements
that affect the whole body energy homeostasis of the
animal [1]. Type 1 fibers are classified as slow fibers and
use oxidative metabolism as a fuel source, making them
highly fatigue-resistant. Conversely, type 2 fibers are
classified as fast fibers, use mainly glycolytic metabolism
and are less resistant to fatigue. Type 2 fibers are further
broken down into three subtypes, known as types 2a, 2x
and 2b, that express corresponding myosin heavy chain
(MyHC) isoforms and have decreasing resistance to fati-
gue. Notably, skeletal muscles are plastic, and fiber-type
switching occurs in response to changes in activity and
other physiological signaling pathways [2-4]. In addition,
skeletal muscle mass is always in a state of hypertrophy
or wasting, based on relative use or disuse, respectively
[5,6]. Skeletal muscle has superior capacity to regenerate
itself upon injury [7].
Skeletal muscle plasticity is mainly maintained by a
subset of cells known as satellite cells [8,9]. These
cells, located beneath the basal lamina of the muscle
fiber, are normally maintained in a quiescent state.
Satellite cells become activated when the muscle
becomes damaged through injury or normal activity.
Once activated the cells will reenter the cell cycle and
undergo a few rounds of division, then differentiate
and fuse with existing muscle fibers to rebuild the
damaged area. Satellite cells in the quiescent state
express paired-box transcription factor 7 (Pax7) [10].
After activation the cells will express Pax7 and myo-
genic differentiation antigen 1 (MyoD) concurrently
while the cells undergo a few rounds of division (pro-
liferation). These proliferating cells eventually with-
draw from the cell cycle and either return to
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quiescence (self-renewal) through downregulation of
MyoD or differentiate through downregulation of Pax7
and upregulation of myogenin. Thus expression of
Pax7 and MyoD distinguishes the status of a cell,
whether it is self-renewing (Pax7+/MyoD-), proliferat-
ing (Pax7+/MyoD+) or differentiating (Pax7-/MyoD+),
respectively [11-13]. Notably, researchers in several
recent studies have demonstrated that the choice
between self-renewal and differentiation of newly
divided satellite cells is dynamically regulated [14-16].
Whereas most proliferating myoblasts divide symmetri-
cally, a subpopulation of cells can divide asymmetri-
cally to give rise to both self-renewal and
differentiating progenies [14-16].
Myogenic factor 5 (Myf5) is also important for skeletal
muscle development and satellite cell function. Myf5
transcripts can first be detected at E8 in the developing
embryo and are important for specifying the cells of the
muscle lineage [17]. Myf5-Cre lineage tracing labels a
majority of satellite cells, which will have become com-
mitted to the myogenic lineage. However, 10% of satel-
lite cells remain Myf5-negative and are thought to be a
population of more primitive, uncommitted stem cells
that can give rise to committed cells through asym-
metric cell division [15]. Myf5-null satellite cells are
defective in transient proliferation prior to differentia-
tion [18,19]. Intriguingly, investigators in recent studies
have demonstrated that brown adipocytes, but not white
adipocytes, are derived from Myf5 lineage progenitors
[20]. Therefore, Myf5-Cre-mediated conditional knock-
out can be used to knock out floxed target genes in
committed myogenic progenitor cells and their descen-
dants (mature skeletal muscles) as well as in brown
adipocytes.
Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear estrogen receptor superfam-
ily and have been shown to be important for the proper
metabolism of fatty acids [21]. There are three PPAR
isoforms (a, δ and g), and each plays a specific role in
metabolism [22-24]. The PPARs are expressed in a wide
range of adult tissues, but each has its own tissue-speci-
fic expression patterns. PPARa is highly expressed in
the liver and heart, PPARδ (also referred to as PPARb,
PPARb/δ or NR1C2) is highly expressed in the intestine
and liver, and PPARg is highly expressed in both brown
and white adipose tissues [21-23,25,26]. The three PPAR
isoforms are ligand-activated receptors that are activated
by fatty acids, fatty acid derivatives and a variety of syn-
thetic compounds [21]. The ligand-binding domains of
PPARs vary slightly, resulting in specific affinity for fatty
acids and synthetic compounds [27]. For example,
GW501516 is one synthetic compound that has been
shown to specifically activate PPARδ with 60- to 1, 000-
fold selectivity over the other isoforms, depending on
cell types and animal species [28,29]. These receptors
must form heterodimers with the retinoid X receptor
(RXR) before they can bind to specific recognition
sequences, called PPAR response elements (PPREs),
which are located in the promoter and intron regions of
a wide variety of target genes [21,30]. The PPARs acti-
vate or repress transcription through the recruitment of
coactivators and corepressors.
PPARδ has been shown to be important for the proper
function of skeletal muscle in gain- and loss-of-function
studies. Synthetic compound-mediated activation or
overexpression of the Pparδ gene in mice causes an
increase in the oxidative capacity of the muscle resulting
from an increase in the number of type 1 oxidative
fibers and a decrease in the number of type 2 glycolytic
fibers [31,32]. These increases in oxidative capacity have
been shown to contribute to an organism’s overall exer-
cise endurance. Along with increases in oxidative capa-
city, transgenic mice also show a decrease in overall
body fat content and individual adipocyte size. Mice
with constitutively active Pparδ can maintain a normal
body weight even when challenged with a high-fat diet,
whereas their wild-type littermates become obese when
fed the same diet. By contrast, skeletal muscle-specific
knockout of Pparδ seems to cause a decrease in oxida-
tive capacity and makes mice prone to obesity and
metabolic disorders [33]. This loss of oxidative capacity
could be due in part to reduced expression of PGC1a,
which is known to play a role in type 1 fiber formation
and maintenance. These results suggest that PPARδ
plays a role in preventing obesity and the development
of metabolic disorders.
Until now all the studies on PPARδ in skeletal muscle
have focused on mature muscle fibers. It remains to be
determined whether PPARδ plays a role in myogenic
satellite cells and postnatal muscle regeneration. PPARδ
has been shown to regulate the proliferation and/or
maturation of several cell types, including mouse
embryonic stem cells, oligodendrocytes, keratinocytes,
endothelial progenitors and cancer cells [34-38]. How-
ever, whether PPARδ positively or negatively regulates
proliferation is highly cell type-specific, and the evidence
presented in the literature has sometimes been contra-
dictory [36]. In the current study, we used a Cre/LoxP-
based conditional mutation approach to remove Pparδ
from the satellite cells to examine its function in muscle
progenitor cells. We show herein that PPARδ is an
important regulator of satellite cell proliferation in vitro
and of muscle regeneration in vivo.
Materials and methods
Animals
All experimental procedures involving the use of mice
were carried out in accordance with Purdue University’s
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Animal Care and Use Committee. C57BL/6J mice con-
taining LoxP sites flanking exon 4, which encodes the
N-terminal zinc finger of the DNA-binding domain of
the Pparδ gene (Pparδf/f), had been generated previously
[39]. These mice were crossed with Myf5-Cre to gener-
ate Myf5-Cre/Pparδf/f offspring for ablation of Pparδ in
Myf5 lineage cells (called “Pparδ-cKO” hereinafter) [40].
Pparδ+/f or Pparδf/f littermates that did not inherit the
Myf5-Cre allele were used as controls (called “wild type”
hereinafter, as these mice express Pparδ normally). Gen-
otyping was done by PCR to confirm the presence of
Cre along with the presence of floxed and wild-type
Pparδ alleles as described by The Jackson Laboratory
under mouse stock numbers 007893 and 005897 (Bar
Harbor, ME, USA).
Cardiotoxin injection
Tibilais anterior (TA) muscles taken from six-week-old
C57BL/6J mice were injured by injection of cardiotoxin
(CTX) (C3987; Sigma-Aldrich, St Louis, MO, USA) to
induce muscle regeneration. The animals were first
anesthetized by intraperitoneal injection of 0.2 ml keta-
mine cocktail/20 g body weight. Ketamine cocktail con-
tains 0.9 ml of ketamine (100 mg/ml), 0.1 ml of xylazine
(100 mg/ml) and 9.0 ml of saline. The hind limbs were
then shaved to expose the belly of the TA and wiped
with 70% ethanol. Next we injected 50 μl of 10 μM
CTX into the belly of the TA muscle. The mice were
allowed to recover on a heating pad for about one hour.
The mice were then harvested at days 5 and 14 after
injection, and their TA muscles were removed for RNA
extraction and histological examination after being fixed
in 4% paraformaldehyde.
Glucose challenge
Glucose tolerance tests were performed on two- and
nine-month-old mice. All mice were fasted for three
hours prior to the start of testing. Blood was collected
from the tip of the tail and tested before (0 minutes)
and 15, 30, 60 and 90 minutes after intraperitoneal
injection of glucose (2 g/kg). Blood glucose levels were
measured using an ACCU-CHEK Active blood glucose
meter system (Roche Diagnostics, Indianapolis, IN,
USA). Body weight data were collected prior to glucose
tolerance testing.
Cell culture
Primary myoblasts were harvested from the limb mus-
cles of mice that were six weeks of age. Limb muscles
were digested in a solution containing 1% collagenase B
(Roche Diagnostics) and 2.4 U/ml Dispase II (neutral
protease, grade II; Roche Applied Science) for 30 min-
utes in an incubator at 37°C with 5% CO2 and triturated
every 15 minutes. The digestion was stopped after 30
minutes using 25 ml of DMEM containing 2% fetal
bovine serum (FBS) and 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, then passed through a
100-μm filter. After filtration, the cells and muscle deb-
ris were pelleted at 250 × g for five minutes and the
DMEM was removed. The cells and muscle debris were
then plated on noncoated plates with Ham’s complete
medium containing 20% FBS, 4 ng/ml basic fibroblast
growth factor and 1% penicillin/streptomycin (p/s) (10,
000 U penicillin/g/ml, 10 mg streptomycin/ml). The
cells and muscle debris were maintained in an incubator
at 37°C with 5% CO2 for three days, and 5 ml of Ham’s
medium were added each day. On the third day, all cells
and muscle debris (with cells attached) were collected
into a 15-ml conical tube and digested with 1 ml of
0.025% trypsin for five minutes at 37°C. Dissociated cells
were resuspended in 10 ml of Ham’s complete medium
and passed through a 30-μm filter, then plated on a col-
lagen-coated plate. Myoblasts were maintained in Ham’s
medium and passed through the filter several times
before they became senescent and were discarded. To
differentiate myoblasts, Ham’s medium was switched to
DMEM containing 5% horse serum with 1% p/s when
cultures reach 80% confluence. For cell-growth analysis,
primary myoblasts from both Pparδ-cKO and wild-type
mice were counted, and 50, 000 cells were seeded into
each well of a six-well plate. Cells were removed from
the plate with trypsin and counted with a hemocyt-
ometer on days 3, 6 and 9 after the initial plating.
Isolation and culture of single myofibers
Single myofiber-carrying satellite cells were isolated as
previously described [41]. Fibers were harvested from the
soleus (SOL) and extensor digitorum longus (EDL) mus-
cles of mice that were six weeks of age. Whole muscles
were removed from the hind limbs by careful handling of
the tendons only. The SOL and EDL muscles were first
placed in 5 ml of DMEM containing 0.2% collagenase I
and then into the water bath at 37°C for 40 minutes
(EDL muscle) or 80 minutes (SOL muscle). The fibers
were then placed into a 6-cm plate with 5 ml of DMEM
and separated from the tendons by careful manipulation
using heat-polished Pasteur pipettes coated with horse
serum to prevent sticking. After the fibers were sepa-
rated, they were fixed immediately for staining or trans-
ferred onto a new plate containing 5 ml of DMEM with
20% FBS and 2% chick embryo extract, then placed in the
incubator at 37°C with 5% CO2 for three days. At the end
of the three days, the fibers were collected, fixed with 2%
paraformaldehyde and prepared for staining.
Immunocytochemistry
Primary myoblasts were grown in chamber slides for
staining. The cells were fixed with 2% paraformaldehyde
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for ten minutes, then washed three times with PBS
before the primary antibody was added. The primary
antibodies used were Pax7 (Developmental Studies
Hybridoma Bank, Department of Biology, University of
Iowa, Iowa City, IA USA), MyoD (sc-20; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and mAb clones
HB287, HB277 and HB283 for MyHC1, MyHC2a and
MyHC2b, respectively (American Type Culture Collec-
tion, Manassas, VA, USA). Cells were incubated with
the primary antibody for one hour at room temperature
on a shaker. After incubation with the primary antibody,
the cells were washed three times with PBS before the
secondary antibody was added. The secondary antibo-
dies used were goat anti-mouse immunoglobulin G2b
(IgG2b) conjugated with Alexa Fluor 647 dye, goat anti-
mouse IgG1 conjugated with Alexa Fluor 568 dye, goat
anti-mouse IgM conjugated with Alexa Fluor 488 dye
(Molecular Probes/Life Technologies, Carlsbad, CA,
USA) and daylight Alexa Fluor 488-conjugated goat
anti-rabbit (Jackson ImmunoResearch Laboratories, Inc,
West Grove, PA, USA). The cells were incubated with
secondary antibody and Hoechst dye (a DNA dye) for
30 minutes. The cells were again washed three times
with PBS before being mounted with Dako Fluorescence
Mounting Medium (Glostrup, Denmark) and covered
with a coverslip. Images were recorded on a Leica
DMI6000 B inverted fluorescence microscope (Leica
Microsystems, Mannheim, Germany).
Histology
The muscles harvested from the hind limbs were
embedded in optimal cutting temperature (O.C.T.) com-
pound (Sakura Finetek USA Inc, Torrance, CA, USA)
and quickly frozen in dry ice-cooled isopentane. Cryo-
sections were cut to 10-μm thickness and placed on
glass slides. For immunohistochemistry, slides were
blocked with blocking buffer (5% horse serum, 2% BSA,
0.2% Triton X-100 and 0.1% sodium azide in PBS) for
two hours prior to antibody staining. The slides were
incubated with primary antibodies for one hour at room
temperature, then washed three times with PBS before
incubation with secondary antibody for 30 minutes.
After three more washes with PBS, the slides were
mounted with Dako Fluorescence Mounting Medium
and covered with a coverslip.
H & E and NADH staining
Sections (10-μm thickness) were first washed with PBS
to remove excess O.C.T. compound, then incubated in
hematoxylin for five minutes, washed and incubated in
1% eosin for 30 seconds. The sections were then dehy-
drated in increasing concentrations of ethanol and
mounted with CytoSeal Mounting Medium (Electron
Microscopy Sciences, Fort Washington, PA, USA),
covered with a coverslip and allowed to dry overnight.
For nicotinamide adenine dinucleotide, reduced
(NADH) staining, sections were washed briefly in PBS
to remove excess O.C.T. compound. The slides were
then incubated in a solution containing 100 mg/ml
NADH and 0.1 g/ml nitroblue tetrazolium (NBT) for 30
minutes at 37°C. The slides were then washed three
times with deionized water. Unbound NBT was removed
from the sections by washing the slides three times each
with 30%, 60% and 90% acetone. The sections were then
washed with deionized water and mounted.
Gene expression
All gene expression data were gathered by real-time
PCR. RNA was extracted from cell culture, whole-mus-
cle and adipose tissue using the RNeasy RNA extraction
kit (QIAGEN, Germantown, MD, USA). RNA was con-
verted into cDNA using Moloney murine leukemia virus
reverse transcriptase and random hexamer primers. The
real-time PCR oligonucleotides are listed in Additional
file 1, Table S1. Samples were then run in a LightCycler
480 System (Roche Applied Science) for 40 cycles. Fold
changes were calculated using the 2-ΔΔCt method.
Western blot analysis
Expression of PPARδ protein in Pparδ-cKO and wild-
type muscles was examined by Western blot analysis as
previously described [32]. Briefly, equal amounts of
nuclear proteins extracted under identical conditions
were run on SDS-PAGE gels and transferred onto poly-
vinylidene difluoride membrane. PPARδ was detected
with rabbit anti-PPARδ antibody from Santa Cruz Bio-
technology (SC-7197).
Statistical analysis
The number of mice used for each experiment is listed
in the figure legend. Every experiment was performed in
triplicate. For the glucose tolerance tests, statistical ana-
lysis was based on area under the curve (AUC) using
the trapezoidal rule. All data are presented as means ±
SEM. P-values were calculated using a two-tailed Stu-
dent’s t-test unless otherwise indicated. All values equal
to 0.05 or less were considered significant and are
denoted by asterisks in the figures.
Results
Characterization of the Pparδ-cKO model
To generate tissue-specific knockout of Pparδ, we used
mice bearing a floxed exon 4 in the Pparδ gene [39].
The presence of Cre will excise exon 4, corresponding
to the N-terminal zinc finger of the DNA binding
domain of PPARδ, and lead to premature stop of trans-
lation and abolish the transcriptional activity of the
resulting truncated PPARδ (Additional file 2, Figure
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S1A). The Pparδf/f mice were bred to mice expressing
Cre recombinase under the control of the endogenous
Myf5 promoter Myf5-Cre (007893; The Jackson Labora-
tory) to generate the Pparδ-cKO mice. Since Myf5 is
expressed in the mesoderm during development, we
expected that PPARδ would be selectively ablated in
several mesodermal tissues that express Myf5, including
skeletal muscle and brown fat (BAT) [20].
To confirm the tissue-specific knockout, we collected
RNA samples from adult skeletal muscle, BAT and
white fat (WAT) and conducted quantitative RT-PCR
(qPCR) analysis. The levels of Pparδ in the Pparδ-cKO
mice compared to their wild-type littermates were
reduced by 7-fold in TA muscle and by 11-fold in BAT,
but they were not changed in WAT (Figure 1A). These
results confirm the tissue-specific knockout and are
Figure 1 Characterization of the PPARδ-cKO model. Blue and green bars represent wild-type (WT) and peroxisome proliferator-activated
receptor δ conditional knockout (Pparδ-cKO) (MUT) tissues, respectively. (A) Relative expression levels of Pparδ in tibialis anterior (TA) muscle,
brown fat and white fat tissues (N = 8 pairs of wild-type and mutant mice) for each tissue type. (B) Quantitative RT-PCR showing the relative
expression levels of Pparδ in whole-muscle tissue, proliferating myoblasts, white fat and brown fat in wild-type mice (N = 8 for each tissue type
and N = 2 for myoblasts). (C) and (D) Expression levels of Ppara in TA muscle (C) and Pparg in TA, brown fat and white fat tissues (N = 8 for
each tissue type) (D). (E) and (F) Expression levels of carnitine palmitoyltransferase 1b (mCPT1b) and Forkhead box class O transcription factor 1
(FoxO1) genes in TA muscles (N = 3).
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consistent with the notion that skeletal muscle and BAT
derive from the Myf5 lineage and WAT derives from a
Myf5-independent lineage [20]. We further confirmed
by Western blot analysis that PPARδ protein levels are
reduced by 60% to 80% in the gastrocnemius muscles of
Pparδ-cKO mice compared to those of wild-type mice
(Additional file 2, Figure S1B). Interestingly, analysis of
relative Pparδ expression in various wild-type tissues
indicated that both proliferating myoblasts (derived
from satellite cells) and WAT expressed much higher
levels of Pparδ compared to whole muscle and BAT
(Figure 1B). Specifically, Pparδ mRNA levels in primary
myoblasts were about 15-fold greater than those in the
TA muscles, suggesting a specific role of PPARδ in
myoblast proliferation. In addition, we found that the
levels of Pparg and Ppara remained unchanged in
Pparδ-cKO compared to wild-type tissues (Figures 1C
and 1D), confirming that Pparδ-cKO did not elicit com-
pensation by other PPAR isoforms. Therefore, any
observed phenotypes are due to specific knockout of
Pparδ in our mouse model.
To understand how PPARδ functions in muscle, we
compared the expression of a number of known PPARδ
target genes in wild-type and mutant TA muscles from
adult mice. The expression of carnitine palmitoyltrans-
ferase 1b (mCPT1b), whose protein regulates the rate-
limiting step for b-oxidation of long-chain fatty acids
[21,24], and Forkhead box class O transcription factor 1
(FoxO1), a PPARδ target that regulates skeletal muscle
metabolism and progenitor cell function [42-44], were
significantly decreased in Pparδ-cKO muscle (Figures 1E
and 1F). The expression of several other known target
genes of PPARδ, including Sirt1, UCP1 and PGC1a, was
not altered in the mutant muscles (Additional file 3, Fig-
ure S2). These results confirm that Pparδ-cKO affects
candidate target gene expression and identify mCPT1b
and FoxO1 as potential target genes regulated by PPARδ
in resting skeletal muscles.
Satellite cell and myoblast proliferation and
differentiation
Adult Pparδ-cKO mice have a reduced number of satel-
lite cells, and Pparδ-null myoblasts exhibited reduced
proliferation and increased differentiation kinetics.
Because proliferating myoblasts expressed high levels of
Pparδ compared to whole muscles (Figure 1B), we
investigated the effect of Pparδ mutation on the satellite
cells in vivo and in myoblasts in culture. Intact single
fibers were isolated from the representative slow (SOL)
and fast (EDL) muscles and stained with Pax7 antibody
to label satellite cells (Figure 2A). At two to three
months old, the mutant mice had, on average, a 40%
reduction in satellite cell numbers in both EDL and
SOL muscles (Figure 2C). Consistent with this
observation, qPCR analysis indicated that satellite cell-
specific Pax7 gene expression was reduced by about
40% in the mutant compared to the wild-type TA mus-
cles (Figure 2D). Interestingly, normal satellite cell num-
bers were detected at three weeks of age, and a nearly
20% reduction was detected at age five weeks in the
Pparδ-cKO compared to the wild-type EDL fibers
(Additional file 4, Figure S3). Furthermore, the number
of 4’, 6-diamidino-2-phenylindole-positive nuclei per
myofiber was reduced in the Pparδ-cKO mice at five
weeks old but not at three weeks old (Additional file 4,
Figure S3). The gradual reduction in satellite cells and
differentiated myonuclei in the Pparδ-cKO muscle dur-
ing postnatal growth suggests that PPARδ is important
for satellite cell proliferation and maintenance.
Next we examined whether the satellite cells asso-
ciated with the isolated fibers were able to proliferate
and differentiate normally using a single-myofiber cul-
ture paradigm to mimic satellite cell activation in vivo
[13,15]. We cultured isolated fibers for three days in
vitro and fixed and stained clusters of myoblasts that
had proliferated on single fibers with antibodies to Pax7
and MyoD (Figure 2B). Previous studies have established
that Pax7+/MyoD-, Pax7+/MyoD+ and Pax7-/MyoD+
cells represent self-renewing, proliferating and differen-
tiating progenies, respectively [11-13]. The relative per-
centage of cells in these three categories was examined.
Compared to the wild type, mutant SOL fibers had half
as many proliferating cells (Pax7+/MyoD+) and twice as
many differentiating cells (MyoD+), whereas the propor-
tion of self-renewing cells (Pax7+) remained the same
between wild-type and mutant fibers (Figure 2E).
Together, these results show that PPARδ is important
for maintaining the proliferation of activated myoblasts
and that loss of PPARδ leads to accelerated myogenic
differentiation.
To further characterize the proliferative defects of
Pparδ-null myoblasts, we examined the expression of
Ki67, a cell proliferation marker, in cultured primary
myoblasts from mutant mice and wild-type littermates
(Figure 3A-B). Real-time PCR analysis confirmed a 60%
reduction in Pparδ expression in newly established cul-
tures of Pparδ-cKO compared to wild-type myoblasts
(Additional file 5, Figure S4A). The percentage of Ki67+
cells and the Ki67 immunofluorescence intensity of the
Pparδ-mutant myoblasts were threefold less than those
of wild-type plates (Figures 3C). Conversely, a PPARδ
agonist, GW501516, significantly increased wild-type
myoblast proliferation (Additional file 5, Figure S4B).
We also plotted the growth curve of wild-type and
mutant myoblasts at days 3, 6 and 9 after they were pla-
ted in culture. Myoblasts from Pparδ-cKO muscle
showed a reduced growth rate compared to myoblasts
from wild-type muscle (Figure 3D). These results
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provide compelling evidence that PPARδ positively regu-
lates myoblast growth and proliferation.
Muscle regeneration after injury is impaired in Pparδ-cKO
animals
To examine whether the reduced rates of proliferation
in the Pparδ-cKO myoblasts result in defects in muscle
regeneration in vivo, we injured the TA muscles of
mutant and wild-type animals at six weeks of age. After
14 days, the mice were killed and the TA muscles were
collected for gene expression and histological analysis.
We examined the regenerating regions under a micro-
scope, and the number of regenerating fibers (small,
centrally located nucleus) and regenerated fibers (large,
eccentrically located nucleus) were counted. Both wild-
type and Pparδ-cKO TA muscles underwent regenera-
tion, but they exhibited marked differences (Figures 4A
and 4B). The mutant muscles had much larger areas of
Figure 2 Reduced satellite cell number and proliferation in Pparδ-cKO mice. (A) Freshly isolated extensor digitorum longus (EDL) muscle
fibers were stained with paired-box transcription factor 7 (Pax7) antibody to label satellite cells. Nuclei were counterstained with 4’, 6-diamidino-
2-phenylindole (DAPI). Scale bar = 25 μm for all panels in parts (A) and (B). (B) Soleus (SOL) muscle fibers were cultured for 72 hours, and the
proliferating satellite cells on the fibers were fixed and stained with Pax7 and myogenic differentiation antigen 1 (MyoD) antibodies. Nuclei were
counterstained with DAPI. Satellite cell status is classified as self-renewed cells (Pax7+), proliferating cells (Pax7+/MyoD+) and differentiating cells
(MyoD+). (C) Quantification of the number of Pax7+ satellite cells per single fiber isolated from the EDL and SOL muscles (N = 360 fibers each
from the SOL and EDL muscles). **P < 0.0001. (D) Relative expression of the Pax7 gene in tibialis anterior (TA) muscles by quantitative PCR (N =
3). (E) Quantification of the number of self-renewed, proliferating and differentiating cells on SOL fibers after culture for 72 hours (N = 20 fibers
for each group).
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small-caliber regenerating fibers that covered almost the
whole muscle sections, whereas the wild-type TA mus-
cles had reduced regenerating areas that were mostly
confined to the center of the section (Figures 4A and
4B). The number of small regenerating fibers was 30%
more, and the number of large regenerating fibers was
20% fewer, in Pparδ-cKO muscles compared to wild-
type muscles (Figure 4C). In addition, the regenerating
Pparδ-cKO TA muscles expressed reduced levels of
MyHC 2b mRNA, the most abundant MyHC isoform in
the TA muscle (Figure 4D), which further confirms the
regenerative defects. The Pparδ-cKO muscles were
eventually able to regenerate after 30 days, suggesting
that Pparδ-cKO mainly causes a delay in muscle
regeneration.
Because Pparδ-cKO myoblasts are defective in prolif-
eration in vitro, we sought to determine whether such
defects exist in vivo during muscle regeneration. We
analyzed Pax7 and MyoD expression (Figures 4F and
4G) at days 3 to 5 post-CTX treatment, at which stage
myoblast proliferation peaks. Consistent with our in
vitro results, we observed a reduction of proliferating
Pax7+/MyoD+ myoblasts and an increase in
differentiated Pax7-/MyoD+ myocytes in the Pparδ-cKO
muscle, together with reduced total myoblast number
per unit area and decreased size of newly regenerated
fibers (Figures 4F to 4I). In addition, we confirmed by
qPCR that Myogenin gene expression was upregulated
in regenerating Pparδ-cKO muscles at this stage (Figure
4J). By contrast, Myf5 was expressed at similar levels in
the mutant and wild-type muscles. These results indi-
cate that the observed regenerative defects of Pparδ-
cKO may be due to reduced proliferation and increased
differentiation kinetics of activated myoblasts.
We also examined the expression of mCPT1b and
FoxO1 genes during muscle regeneration at day 5 after
CTX treatment, when damaged muscles are not yet
regenerated and satellite cell proliferation peaks [8].
Interestingly, expression of mCPT1b was unchanged but
FoxO1 expression was reduced in the Pparδ-cKO mus-
cles compared to wild-type muscles during muscle
regeneration (Figure 4E), suggesting that PPARδ may
activate FoxO1 in proliferating myoblasts and that
mCPT1b is a PPARδ target only in mature muscle
fibers. Together with our earlier observation that Pparδ
is expressed at much higher levels in proliferating
Figure 3 Defective growth and proliferation of primary myoblast cells derived from Pparδ-cKO muscles. (A) and (B) Representative
images of Ki67 staining that specifically labeled proliferating primary myoblasts: Ki67 staining (red) and 4’, 6-diamidino-2-phenylindole (DAPI)
staining (blue). Scale bar = 50 μm. (C) Relative Ki67 signal intensity in wild-type and mutant myoblast cultures. The intensity of Ki67 and DAPI
staining and the number of pixels were measured using Photoshop software (Adobe Systems Inc, San Jose, CA, USA). The ratio of Ki67 intensity
values to DAPI intensity values was also quantified using Photoshop (N = 3). (D) Growth curve of wild-type and mutant myoblasts after nine
days in culture (N = 3).
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Figure 4 Defective regeneration of skeletal muscles and gene expression patterns in Pparδ-cKO mice after injury with cardiotoxin. (A)
and (B) Tibialis anterior (TA) muscles from six-week-old wild-type and peroxisome proliferator-activated receptor δ conditional knockout (Pparδ-
cKOmice were injected with cardiotoxin (CTX) to induce injury. The mice were allowed to recover for 14 days before their muscles were
harvested and processed for staining. Small and large fibers (indicating regenerating and nonregenerating fibers, respectively) were counted.
Scale bars = 50 μm for parts (A) and (B) and for parts (F) and (G). (C) Quantification of regenerating and nonregenerating fibers after injury with
CTX (N = 3 pairs of mice, with five sections taken from each mouse). (D) Relative mRNA expression level showing reduced myosin heavy chain
isoform 2b (MyHC-2b) in mutant muscle after injury with CTX (N = 4). (E) Relative mRNA expression levels of Pparδ target genes in the TA
muscle after injury with CTX (N = 4). (F) and (G) Cryosections of regenerating wild-type (F) and mutant (G) mice at day 5 after injury with CTX.
The sections are labeled with paired-box transcription factor 7 (Pax7) (red), myogenic differentiation antigen 1 (MyoD) (green) and 4’, 6-
diamidino-2-phenylindole (DAPI) (blue). Arrows, arrowheads and asterisks indicate examples of Pax7+/MyoD-, Pax7-/MyoD+ and Pax7+/MyoD+
myoblasts, respectively. (H) The number of total myoblasts labeled by Pax7 and/or MyoD per unit area counted from 8 to 13 areas. (I)
Percentage distribution of Pax7+/MyoD-, Pax7+/MyoD+ and Pax7-/MyoD+ myoblasts in regenerating wild-type and mutant TA muscles at day 5
after injury with CTX. (J) Relative mRNA expression levels of Myf5 and Myogenin in TA muscles at day 3 after injury with CTX (N = 3). *P < 0.05
by single-tailed Student’s t-test.
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myoblasts compared to mature muscles (Figure 1B),
these results suggest a critical role of PPARδ in satellite
cell function in vivo.
Pparδ-cKO does not alter myosin heavy chain isoforms
Because Pparδ overexpression increases oxidative mus-
cle fiber types [32], we sought to determine whether
Pparδ-cKO causes any changes in fiber-type distribution.
We labeled MyHC protein isoforms with a panel of
mAbs (Figures 5A to 5D). We chose the EDL and SOL
muscles to represent fast and slow muscle types, respec-
tively. To overcome potential bias associated regiona-
lized distribution of fiber types within a muscle [45], we
enumerated all muscle fibers in the entire muscle (Fig-
ures 5A to 5D). No difference in the percentage of each
fiber type was found between mutant and wild-type ani-
mals in either the EDL or SOL muscle at six weeks old
(Figure 5E). To further determine whether there are
Figure 5 Normal fiber-type distributions in extensor digitorum longus and soleus muscles of six-week-old Pparδ-cKO mice. (A) through
(D) Immunostained sections showing the distribution of fiber types in the extensor digitorum longus (EDL) and soleus (SOL) ("C-” denotes wild-
type littermate control and “M-” denotes Pparδ-cKO): myosin heavy chain isoform 1 (MyHC-1) (red), MyHC-2a (blue), MyHC-2b (green), MyHC-2x
(black) and laminin (white). The basal lamina surrounding each fiber is shown. Scale bar = 1 mm. (E) Percentage distribution of each fiber type
in the EDL and SOL muscles (N = 4 pairs of littermates.
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changes in muscle oxidative metabolism without chan-
ging MyHC isoform expression, we carried out NADH-
tetrazolium reductase (NADH-TR) staining of the SOL
and EDL muscles. NADH-TR staining marks ATPase
activity that is correlated to oxidative capacity (type 1
fibers are highly oxidative and darkly stained, type 2a
fibers are intermediate fibers and lightly stained and
type 2b fibers are glycolytic and unstained) (Additional
file 6, Figures S5A to S5D). In agreement with our
MyHC isoform staining experiments, there were no dif-
ferences in NADH activity between the Pparδ-cKO and
wild-type mice in either the EDL or the SOL muscles
(Additional file 6, Figures S5E and S5F). These results
demonstrate that Pparδ-cKO does not lead to changes
in muscle fiber type or oxidative capacity in young
animals.
Old Pparδ-cKO mice become obese and have impaired
glucose clearance
PPARδ is an important regulator of muscle energy
metabolism. Therefore, we tested the body weight and
insulin sensitivity in young and old mutant mice. Young
Pparδ-cKO mice (two months of age) did not differ sig-
nificantly in body weight compared to their sex-matched
wild-type littermates (Figure 6A). However, older
mutant mice (nine months of age) were about 25% hea-
vier on average than their wild-type littermates (Figure
6B). Next we measured the rate of insulin-mediated glu-
cose clearance in the mutant and wild-type mice. The
amount of glucose in the blood was measured before (0
minutes) and 15, 30, 60 and 90 minutes after intraperi-
toneal injection of 2 g/kg glucose (Figures 6C and 6D).
Again, young mice showed no differences in the rate of
insulin-stimulated glucose uptake as measured by AUC
analysis of the glucose tolerance curves (Figure 6E).
Strikingly, older mutant mice showed a reduced rate of
glucose uptake; their blood glucose levels spiked higher
than those of the wild-type mice and took longer to
clear from the blood (Figure 6D), resulting in significant
increases in the AUC in every time period measured
(Figure 6F). These results suggest that the older mice
had developed glucose intolerance and an obese pheno-
type even when fed a normal diet.
Discussion
The results produced by our Pparδ-cKO model establish
a previously unappreciated role of PPARδ in skeletal
muscle progenitor cell proliferation. The specificity of
the Pparδ-cKO mouse model is demonstrated by
reduced Pparδ mRNA expression in both the skeletal
muscle and BAT, known to be derived from Myf5 line-
age cells. In contrast, Pparδ expression was unchanged
in WAT, which is derived from a Myf5-independent
lineage [20]. The residual Pparδ expression detected in
Pparδ-cKO whole muscle and BAT (10% to 20% of
wild-type levels) is probably due to non-Myf5 lineage
cells’ residing in these tissues, such as nerve cells (neural
branches and Schwann cells), vessel-associated cells
(blood, lymph, endothelial and smooth muscle cells) and
interstitial connective tissue-associated cells (fibroblasts
and white adipocytes). In addition, because Myf5-Cre is
expressed in about 90% of satellite cells [15], a small
fraction of Myf5- satellite cells would still have normal
levels of Pparδ expression. We nevertheless observed
proliferative defects in satellite cells in vitro and muscle
regeneration in vivo. Further studies using other Cre
lines with improved efficiency of Pparδ deletion in satel-
lite cells would help to better address the muscle-regen-
erative defects.
Mice lacking PPARδ in their skeletal muscles are born
at normal ratios and are viable. These animals do not
appear to have any noticeable defects in body weight or
response to glucose early in life. There was no difference
in total fiber number or percentage of each fiber type in
representative slow (SOL) and fast (EDL) muscles. How-
ever, old mice (eight to nine months old) were signifi-
cantly fatter than their wild-type littermates and were
found to have developed glucose intolerance. This phe-
notype in the aged mouse is similar to that reported in
another transgenic mouse model in which conditional
mutation of Pparδ in mature skeletal muscles is
mediated by human a-skeletal actin promoter-driven
Cre in the transgenic mouse [33]. In that mouse model
(Pparδskm-/-), a reduction in the oxidative capacity and
muscle fiber-type switching are also detected, whereas
such changes are not evident in the Pparδ-cKO mouse
model used in our study. The discrepancy between
these observations may be due to the genetic back-
ground and nutrition status (that is, diet composition)
of the mice used and the different techniques used for
fiber typing. The previous study used qPCR analysis to
show increases in MyHC1 and MyHC2b transcripts in
the gastrocnemius muscle [33]. As many muscle fibers
express multiple MyHC transcripts, small changes in
these transcripts may not be sufficient to induce fiber-
type switching [46]. In our current study, we used
MyHC isoform-specific mAbs to unambiguously identify
fiber types, and we examined all fibers within the entire
muscle to eliminate bias due to regional clustering of
specific fiber types within the same muscle. We have
therefore provided strong evidence that Pparδ-cKO does
not lead to an overt switch of muscle fiber type in
young animals based on MyHC isoform protein
expression.
We show herein that the expression levels of Pax7 are
significantly reduced in the whole muscle of Pparδ-cKO
mice. Because Pax7 is a satellite cell-specific marker
[10], this observation suggests a reduction in satellite
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cell number, which we confirmed by our later results
showing that Pparδ-cKO mice have fewer satellite cells
in vivo. Our single-fiber culture model that mimics
satellite cell activation in vivo further demonstrates that
there are fewer proliferating satellite cells and increased
numbers of differentiating cells in Pparδ-cKO mice. In
vitro growth and proliferation of Pparδ-cKO satellite
cell-derived primary myoblasts were also reduced, as
shown by the decreased number of cells expressing the
cell proliferation marker Ki67 and the increased
population doubling time based on the cell growth
curve. Conversely, the PPARδ agonist GW501516 stimu-
lates myoblast proliferation. These results provide com-
pelling evidence that PPARδ acts to facilitate satellite
cell proliferation.
Recent studies have shown that PPARδ promotes the
proliferation of several cell types. PPARδ activation has
been shown to increase the proliferation and migration
of endothelial progenitors as well as the number of
hematopoietic stem cells in the bone marrow [34,47,48].
Figure 6 Age-dependent increases in body weight and glucose tolerance in Pparδ-cKO mice. (A) and (B) Body weights of female wild-
type mice and mutant littermates at two and nine months old (N = 6). (C) and (D) Blood glucose concentration at different time points
following intraperitoneal injection of glucose (2 g/kg). The mice were fasted for three hours prior to glucose injection. Glucose concentration
was measured using an ACCU-CHEK Active blood glucose meter system (Roche Diagnostics, Indianapolis, IN, USA) (N = 3 pairs of female
littermates). (E) and (F) Area under the curve (AUC) analysis the of glucose tolerance test results shown in parts (C) and (D), respectively.
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In addition, PPARδ has been shown to be essential for
high glucose-stimulated proliferation of embryonic stem
cells [35]. Moreover, PPARδ is an important regulator of
the proliferation of several cancer cell types [49,50]
(older references are reviewed by Peters and Gonzalez
[36]). The PPARδ antagonists SR13904 and GSK0660,
which block PPARδ activation, have been shown to
reduce cell proliferation [50,51]. The role of PPARδ in
cell proliferation has been shown to be due to its activa-
tion of the phosphatidylinositol 3-kinase and AKT path-
ways [34,38], which has been shown to be important in
preventing apoptosis and enhancing cell proliferation by
triggering cells to overcome cell-cycle arrest and initiat-
ing cell proliferation [52,53]. Importantly, AKT signaling
plays critical roles in skeletal muscle progenitor cell
function and muscle hypotrophy [4,5,54].
A number of other studies have shown that PPARδ
promotes differentiation and inhibits (or has no effect
on) proliferation in many cell types, particularly kerati-
nocytes, smooth muscle cells, cardiac fibroblasts and
several cancer cell lines (extensively reviewed by Peters
and Gonzalez [36] and Foreman et al. [55]). Therefore,
whether PPARδ promotes terminal differentiation or cell
proliferation is highly cell type-specific [36]. Intriguingly,
investigators in a recent study demonstrated that PPARδ
can exert its transcriptional activation or repression
both ligand-dependently and ligand-independently in a
target-specific manner [56]. Such variations in the mode
of PPARδ action probably account for the paradoxical
effects of PPARδ in different cell types or even in the
same cell type. More research is needed to elucidate
how PPARδ regulates satellite cell proliferation and
whether it also functions at later stages of myogenesis
(see discussion below).
Pparδ-cKO animals showed delayed muscle regenera-
tion after injury with CTX. We found that, compared to
their wild-type littermates, transgenic mice lacking
PPARδ in the skeletal muscle had a reduced proportion
of proliferating myoblasts and that the regenerated
fibers were smaller in caliber at both five days and two
weeks after CTX injury. These results are consistent
with our observations that these animals had fewer
satellite cells and that Pparδ-deficient satellite cells have
reduced proliferative potential in vitro. Because satellite
cells are responsible for skeletal muscle regeneration,
reductions in satellite cell number and defective satellite
cell proliferation may have resulted in the observed
delay in muscle regeneration. In addition to decreased
satellite cell proliferation, loss of PPARδ in myofibers
may have contributed to the observed defects in muscle
regeneration. Moreover, other signaling mechanisms
may have compensated for the loss of PPARδ in our
conditional mutant, leading to completion of muscle
regeneration at a later time. Coincidentally, the
incidence of sarcopenia (age-related muscle loss) has
been shown to correlate with reduced levels of PPARδ,
and pharmacological activation of PPARδ has been
shown to reduce the incidence of sarcopenia by increas-
ing nuclear accretion in myofibers [57]. These results
support the notion that PPARδ is important for proper
skeletal muscle regeneration in response to injury or
daily wear and tear (maintenance) by increasing satellite
cell proliferation and promoting fusion of differentiated
myocytes in vivo.
We examined the expression levels of several pre-
viously identified PPARδ target genes to understand
how PPAR functions in skeletal muscle and satellite
cells. Our results show that the expression of both
mCPT1b and FoxO1 is reduced in mature uninjured
muscles of the Pparδ-cKO mice, suggesting that they
are molecular targets of PPARδ under resting condi-
tions. Since PPARδ has been shown by many groups to
be a regulator of oxidative capacity in skeletal muscle
[21], it is not surprising that key players in the lipid oxi-
dation pathway would be downregulated after removal
of PPARδ. Interestingly, mCPT1b expression is not sig-
nificantly reduced in Pparδ-cKO muscle at day 5 during
regeneration. At this time point, degenerated muscle
fibers have not been replaced by new fibers and myo-
blast proliferation is at the peak stage [8]. This result
seems to suggest that mCPT1b is a target of PPARδ in
mature resting muscles, but not in proliferating myo-
blasts. Of all the PPARδ target genes we examined,
FoxO1 was the only gene whose expression was downre-
gulated in both resting and regenerating muscles of
Pparδ-cKO mice. The downregulation of FoxO1 in
Pparδ-cKO regenerating muscle indicates that FoxO1
may act at downstream of PPARδ in regulating myoblast
proliferation and inhibiting its differentiation. Indeed, it
has been shown that constitutive activation of FoxO1
inhibits myoblast differentiation [44]. However, FoxO1
also acts at later stages of myogenesis, during the fusion
of differentiated myocytes into myotubes [58]. These
previous studies and our present results suggest that
PPARδ acts through FoxO1 in both satellite cells and
mature muscle fibers but has distinct functions in these
cell types. It regulates the proliferation of satellite cells
and fusion of muscle fibers. These combined effects of
PPARδ’s acting through FoxO1 explain the regenerative
defects seen in the Pparδ-cKO muscles.
PPARδ has also been implicated in the treatment of
degenerative muscle diseases such as Duchenne muscu-
lar dystrophy (DMD), which is caused by the mutation
of the dystrophin gene [59,60]. One research group
showed that PPARδ activation by the agonist
GW501516 increased the expression of utrophin A, a
key member of the dystrophin-associated protein com-
plex, in the C2C12 myoblast cell line [61]. PPARδ has
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been suggested to be a direct transcriptional regulator of
utrophin A in vivo [43]. Intriguingly, utrophin A overex-
pression can improve the integrity of the sarcolemma,
protect muscles from contraction induced damage and
help to alleviate muscle wasting and slow down the dis-
ease progression of DMD [62]. Therefore, understanding
how PPARδ functions in skeletal muscle tissue and its
progenitor cells has important implications for muscle
regeneration and the treatment of degenerative muscle
diseases.
Conclusions
Our in vivo and in vitro analyses of myogenic lineage
specific Pparδ gene knockouts demonstrate a critical
role of PPARδ in satellite cell proliferation and postnatal
regeneration of skeletal muscles. In addition, we provide
evidence for a role of PPARδ in regulating muscle insu-
lin resistance, as indicated by the glucose tolerance test
results. However, we were unable to detect overt
changes in skeletal muscle fiber types by MyHC iso-
form-specific antibody labeling. These results not only
support the previously established role of PPARδ in
muscle energy metabolism and insulin sensitivity but
also demonstrate a novel role of PPARδ in muscle pro-
genitor cell function. These results have implications for
the treatment of muscular dystrophies and muscle-wast-
ing conditions by targeting PPARδ signaling at the stem
cell level.
Additional material
Additional file 1: Table S1 Primer sequences for quantitative PCR.
Additional file 2: Figure S1 Pparδ-cKO strategy. (A) Peroxisome
proliferator-activated receptor δ (Pparδ) gene structure with exons
numbered sequentially. Note that LoxP sequences are inserted before
and after exon 4 encoding the DNA-binding domain of PPARδ. In the
presence of Cre (driven by Myf5 locus in this study), exon 4 is excised,
resulting in premature stop in translation and generation of a short,
truncated protein without a DNA-binding domain. (B) Representative
Western blot showing the relative expression of PPARδ protein in the
wild-type (WT) and Pparδ-conditional knockout (Pparδ-cKO)
gastrocnemius muscles. The upper nonspecific band serves as an
indicator of the relative amount of total protein loaded onto the gel.
Additional file 3: Figure S2 Relative expression of PPARδ target
genes in mature noninjured muscles. RNA samples isolated from the
tibialis anterior (TA) muscles of six-week old mice were used for
quantitative PCR analysis. (A) UCP1. (B) Sirt1. (C) PGC1a. N = 4 for UCP1
and Sirt1 and N = 6 for PGC1a.
Additional file 4: Figure S3 Satellite cell (A) and myonuclei (B)
abundance in extensor digitorum longus fibers of wild-type and
Pparδ-cKO mice during postnatal growth at three and five weeks
old. Two pairs of mice at each age were used. The satellite cell number
was averaged from 30 to 37 fibers, and myonuclei were averaged from
20 to 40 fibers.
Additional file 5: Figure S4 Role of Pparδ in primary myoblast
proliferation. (A) Relative expression of the peroxisome proliferator-
activated receptor δ (Pparδ) gene in mutant and wild-type myoblasts at
passages 3 and 4 (N = 4). (B) Percentage of proliferating cells (Ki67+) in
wild-type primary myoblasts at 24 hours after control (dimethyl sulfoxide
vehicle) and 100 nM PPARδ agonist GW501516 treatments (N = 10).
Additional file 6: Figure S5 NADH-tetrazolium reductase staining
showing the relative abundance of oxidative fibers in Pparδ-cKO
and wild-type skeletal muscles. Staining shows the three different fiber
types. Oxidative fibers (type 1) are darkly stained, intermediate fibers
(type 2a) are moderately stained and glycolytic fibers (types 2b and 2x)
are unstained. (A) and (B) Representative images of fast muscles
(extensor digitorum longus (EDL)). (C) and (D) Representative images of
slow muscles (soleus (SOL)). (E) and (F) Relative nicotinamide adenine
dinucleotide, reduced (NADH), intensity levels between peroxisome
proliferator-activated receptor δ (PPARδ) wild-type and PPARδ-conditional
knockout (Pparδ-cKO) animals at six weeks of age (N = 3).
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